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THE Royal Veterinary College (RVC) will be recruiting for a clinical trial to evaluate the 8 
effect of pregabalin in dogs suffering neuropathic pain from Chiari-like malformation and 9 
syringomyelia (CM/SM). We would be grateful if colleagues could contact us if dogs are 10 
presented to their clinics with suspected or confirmed CM/SM based on a recent or pending 11 
brain and spinal cord MRI diagnosis. Suitable dogs should only have received non-steroidal 12 
anti-inflammatory drugs as analgesics.  13 
CM/SM are two closely linked conditions associated with an array of neurological signs that 14 
may severely impact upon quality of life. Estimates for prevalence of CM (with or without 15 
SM) in the cavalier King Charles spaniel range from 92 to 100 per cent (Couturier and others 16 
2008, CerdaGonzalez and others 2009). Neuropathic pain is the most important and 17 
consistent clinical sign of CM/SM (Plessas and others 2012), and, in humans, is considered to 18 
be one of the most painful and challenging chronic pain syndromes to treat. However, it may 19 
be difficult to localise in veterinary patients because of animals’ inability to accurately self-20 
report the full experience. We have established a multifaceted approach to quantify 21 
objectively the level of pain, as well as an owner questionnaire to assess observed behaviours 22 
correlated with neuropathic pain. Many different drugs have been proposed and are used for 23 
the management of the clinical signs but, for some of them, there is currently no evidence of 24 
their efficacy. Analgesic selection may depend on severity of pain perceived. Recently, drugs 25 
used in the management of neuropathic pain in humans have been used in dogs, such as the 26 
anticonvulsant pregabalin (Rusbridge and Jeffery 2008). The pharmacological profile of 27 
pregabalin suggests that a dosing schedule of every 12 hours may be appropriate. This is an 28 
advantage compared with gabapentin, which requires more frequent dosing to maintain 29 
minimum efficacious plasma concentrations (KuKanich 2013). To date, there is no objective 30 
data on the efficacy of pregabalin for treatment of neuropathic pain in dogs. The objective of 31 
the study is to evaluate the efficacy of pregabalin on the treatment of neuropathic pain and to 32 
establish the effective plasma concentration window for therapeutic drug monitoring. 33 
Assessment of the efficacy will be evaluated with the objective measurements and an owner 34 
questionnaire. The study is approved by the Royal Veterinary College Ethical Committee 35 
(URN 2013 1243). Colleagues who would like further information regarding the study or 36 
who have suitable cases can contact us via the study e-mail address: neuropathicpain@rvc. 37 
ac.uk or by calling 01707 666605. 38 
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